Key facts
- It has raised $1.3M; the latest was Early Stage VC in Jul 2024.
- Notable investors include Japan External Trade Organization, Intellectual Property Acceleration Program for Startups, NCB Capital (Fukuoka), QB Capital, Waseda University Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ANRis
- ·The full record, as it builds
Funding rounds
No funding rounds for ANRis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ANRis
Operator of a therapeutics platform intended to research, develop, manufacture, and sell drugs for nucleic acid medicine. The company's platform enables the precise targeting of only mutated genes, overcoming the limitations of conventional siRNA approaches that can suppress normal mRNA by selectively silencing disease-causing genes without disrupting normal cellular processes, enabling patients to access transformative treatments.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2023
- Employees
- 3
- Website
- anris.jp/
- Ownership
- Privately Held (backing)
ANRis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ANRis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ANRis in its N-PORT filings yet. We sweep new filings monthly.